Thymosin beta4 is cytoprotective in human gingival fibroblasts

Thymosin beta-4 (TB-500) has well-documented healing properties in skin, corneal, and cardiac tissue, but this study by Reti, Kwon, Qiu, and colleagues, published in the European Journal of Oral Sciences, investigated whether these protective effects extend to oral tissues.

The researchers exposed human gingival fibroblasts to various damaging agents — chlorhexidine digluconate, commercial mouthwash formulations, carbamide peroxide (used in teeth whitening), and tumor necrosis factor-alpha (TNF-alpha). They then measured whether thymosin beta-4 treatment could protect cells from damage, reduce inflammation, and prevent programmed cell death.

The results confirmed thymosin beta-4's broad cytoprotective capabilities. The peptide significantly suppressed the secretion of interleukin-8 (IL-8) following TNF-alpha stimulation, demonstrating potent anti-inflammatory effects. It successfully protected gingival fibroblasts from damage caused by chlorhexidine, mouthwash formulations, and carbamide peroxide. TB-4 also prevented apoptosis induced by both TNF-alpha exposure and chlorhexidine treatment.

This study extends the known protective profile of thymosin beta-4 to oral tissues, reinforcing the peptide's role as a versatile cytoprotective agent. The combination of anti-inflammatory, anti-apoptotic, and cell-protective properties demonstrated here aligns with TB-500's documented benefits in other tissue systems, suggesting its healing potential extends throughout the body.